十全大补汤治疗韩国手足冷过敏患者疗效与安全性的先导性随机双盲安慰剂对照平行组临床试验方案
本研究为一项先导性、随机、双盲、两臂、安慰剂对照、平行组、多中心临床试验方案,计划从五家大学医院招募19-59岁手足冷过敏女性60例,按1:1随机分配至十全大补汤组或安慰剂组,每日三次每次3克,持续8周,主要结局为手足冷过敏视觉模拟评分,旨在评估十全大补汤治疗手足冷过敏的疗效与安全性并为完整随机临床试验提供可行性依据。
要点
- 十全大补汤在韩国广泛用于手足冷过敏治疗,但尚未在临床试验中评估其疗效。
- 本先导试验计划纳入60例19-59岁手足冷过敏女性,随机1:1分配至十全大补汤组或安慰剂组。
- 干预为每日三次每次3克十全大补汤或安慰剂,持续8周,主要结局为视觉模拟评分。
核心结论
- 本研究将是首个探讨十全大补汤治疗手足冷过敏疗效与安全性的试验,为韩国草药治疗手足冷过敏提供基础临床信息并为设计完整随机临床试验提供临床依据。
研究设计与样本
- 本研究为先导性、随机、双盲、两臂、安慰剂对照、平行组、多中心临床试验。
- 计划从五家大学医院招募19-59岁手足冷过敏女性,共60例受试者按1:1比例随机分配至十全大补汤组或安慰剂组。
- 受试者每日三次接受3克十全大补汤或安慰剂,持续8周。
- 主要结局指标为手足冷过敏视觉模拟评分,次要结局指标为使用温度计测量的手部和足部体温变化以及韩国版世界卫生组织生活质量简表。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cold hypersensitivity in the hands and feet (CHHF) is frequent in Asian countries including Korea. The quality of life can be degraded by the symptoms of CHHF. In particular, gynecological disorders such as menstrual pain, infertility, leucorrhea, and irregular bleeding may be related to CHHF. Sipjeondaebo-tang (SDT) is widely used in the treatment of various diseases including CHHF by balancing Yin and Yang, restoring the deterioration of physiological function, and improving immunity. However, the efficacy of SDT in the treatment of CHHF has not been assessed in clinical trials. Therefore, we aimed to investigate the feasibility of a full randomized clinical trial of SDT for the treatment of CHHF in Korean women through this trial. METHODS: This study will be a pilot, randomized, double-blind, two-arm, placebo-controlled, parallel-group, multicenter clinical trial. Women aged 19-59 years who present with CHHF will be recruited from five university hospitals. A total of 60 subjects will be randomly assigned to a treatment group (SDT) or a placebo group at a 1:1 ratio. The subjects will receive 3 g of either SDT or placebo three times daily for 8 weeks. The primary outcome measures will be the Visual Analogue Scale scores of CHHF. The secondary outcome measures will be changes in body temperature in both the hands and the feet as measured using a thermometer and the Korean version of the World Health Organization Quality of Life Scale Abbreviated Version. DISCUSSION: This will be the first trial to investigate the efficacy and safety of SDT in the treatment of CHHF. This study will provide basic clinical information regarding Korean herbal medicine treatment of CHHF and a clinical basis for designing a full randomized clinical trial. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03374345 . Registered on 15 February 2018.
引用
- Ko Y, Sun SH, Han IS, et al. The efficacy and safety of Sipjeondaebo-tang in Korean patients with cold hypersensitivity in the hands and feet: a protocol for a pilot, randomized, double-blind, placebo-controlled, parallel-group clinical trial. Trials. 2019. PMID: 30987667. doi:10.1186/s13063-019-3286-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。